MedTrace Logo

A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the Body

NCT05633862 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-11-28

Study results available
· View outcomes & findings →

Summary

The main objectives of this trial are to investigate pharmacokinetics, safety and tolerability of BI 1015550 in Chinese healthy male and female subjects following administration of single doses.

Conditions

  • Healthy

Interventions

DRUG

BI 1015550

A single film-coated tablet BI 1015550 taken orally after an overnight fast of at least 10 hours.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-13
Primary Completion
2023-03-16
Completion
2023-03-17

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05633862 on ClinicalTrials.gov